Hochmaligne Non-Hodgkin Lymphome beim alten und geriatrischen Patienten

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Das hochmaligne Non-Hodgkin Lymphom ist eine aggressiv verlaufende Erkrankung, die überwiegend aus B-Lymphozyten hervorgeht. Grundsätzlich ist das aggressive Non-Hodgkin Lymphom eine Erkrankung, die im höheren Lebensalter auftritt. Das mediane Alter zum Zeitpunkt der Diagnosestellung beträgt ca. 65 Jahre. Therapie der Wahl ist die Systemtherapie bestehend aus dem monoklonalen Antikörper Rituximab und der Kombinationschemotherapie nach dem CHOP Protokoll. Begleitet wird die Therapie von einer anti-infektiösen Supportivtherapie. Die systemische, chemotherapeutische Behandlung erfolgt sowohl bei alten als auch sehr alten Patienten mit einem kurativen Behandlungsziel. Allerdings muss insbesondere bei sehr alten Patienten >80 Jahre die Therapie dosisreduziert nach dem R-mini CHOP verabreicht werden. Neben dem Stadium der Erkrankung wird die Prognose der Erkrankung entscheidend vom Allgemeinzustand bestimmt.

Literatur

  1. Bergenthal N, Will A, Streckmann F, Wolkewitz KD, Monsef I, Engert A, Elter T, Skoetz N (2014) Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev (11):CD009075Google Scholar
  2. Bittenbring J, Neumann F, Altmann B et al (2014) Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of DLBCL patients treated with, but not without rituximab. J Clin Oncol (im Druck). https://www.dshnhl.org/dshnhl/vitamin-d/. Zugegriffen am 15.08.2017
  3. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin’s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817–1826CrossRefPubMedGoogle Scholar
  5. Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525–533CrossRefPubMedGoogle Scholar
  6. Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S (2014) Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 19(12):1249–1257CrossRefPubMedPubMedCentralGoogle Scholar
  7. Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, Hänel M, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rübe C, Pfreundschuh M (2014) Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32(11):1112–1118CrossRefPubMedGoogle Scholar
  8. Howlander N et al. SEER Cancer Statistics Review, 1975–2012. National Cancer Institute, BethesdaGoogle Scholar
  9. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31(22):2765–2772CrossRefPubMedGoogle Scholar
  10. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 129(5):597–606CrossRefPubMedGoogle Scholar
  11. Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, Iriyama N, Kobayashi S, Takeuchi J (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079–1084CrossRefPubMedGoogle Scholar
  12. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96(12):1888–1890CrossRefPubMedPubMedCentralGoogle Scholar
  13. Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M, Fondazione Italiana Linfomi (2014) Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma 55(1):38–43CrossRefPubMedGoogle Scholar
  14. Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C (2014) Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 25(9):1800–1806CrossRefPubMedGoogle Scholar
  15. Naito Y, Sasaki H, Takamatsu Y, Kiyomi F, Tamura K (2016) Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients. J Clin Exp Hematop 56(1):43–49CrossRefPubMedGoogle Scholar
  16. Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol.  https://doi.org/10.1111/bjh.14232. [Epub vor Druck]Google Scholar
  17. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d’Etude des Lymphomes de l’Adulte (GELA) Investigators (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460–468CrossRefPubMedGoogle Scholar
  18. Pfreundschuh M (2016) Current therapeutic strategies for diffuse large B cell lymphoma. Internist (Berl) 57(3):214–221CrossRefGoogle Scholar
  19. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105–116CrossRefPubMedGoogle Scholar
  20. Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N (2014) Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol 32(36):4127–4133CrossRefPubMedGoogle Scholar
  21. Schans SA van de, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280–1286Google Scholar
  22. Siegel AB, Lachs M, Coleman M, Leonard JP (2006) Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma 7(1):65–69CrossRefPubMedGoogle Scholar
  23. Swerdlow SH et al (Hrsg) (2008) WHO classification of tumours of hematopoetic and lymphoid tissues, 4. Aufl. IARC, LyonGoogle Scholar
  24. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRefGoogle Scholar
  25. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M, Guidelines Committee ESMO (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116–v125CrossRefPubMedGoogle Scholar
  26. Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M, Italian Lymphoma Foundation (FIL) (2015) Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 56(4):921–926CrossRefPubMedGoogle Scholar
  27. Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin Lymphoma Study Group (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22(8):1872–1877.  https://doi.org/10.1111/bjh.14232. [Epub vor Druck]CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik 2 – Hämatologie, Onkologie, Immunologie, PalliativmedizinSt.-Vincentius-Kliniken KarlsruheKarlsruheDeutschland

Section editors and affiliations

  • Ulrich Wedding
    • 1
  1. 1.Abteilung für PalliativmedizinUniversitätsklinikum Jena, Klinik für Innere Medizin IIJenaDeutschland

Personalised recommendations